These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33920751)

  • 1. Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis.
    Habig G; Smaltz C; Halegoua-DeMarzio D
    Metabolites; 2021 Apr; 11(4):. PubMed ID: 33920751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models.
    Nachit M; De Rudder M; Thissen JP; Schakman O; Bouzin C; Horsmans Y; Vande Velde G; Leclercq IA
    J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):144-158. PubMed ID: 33244884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis.
    Bhanji RA; Narayanan P; Allen AM; Malhi H; Watt KD
    Hepatology; 2017 Dec; 66(6):2055-2065. PubMed ID: 28777879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis.
    Chakravarthy MV; Siddiqui MS; Forsgren MF; Sanyal AJ
    Front Endocrinol (Lausanne); 2020; 11():592373. PubMed ID: 33424768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease.
    Zambon Azevedo V; Silaghi CA; Maurel T; Silaghi H; Ratziu V; Pais R
    Front Nutr; 2021; 8():774030. PubMed ID: 35111794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease.
    Iwaki M; Kobayashi T; Nogami A; Saito S; Nakajima A; Yoneda M
    Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease.
    Zachou K; Azariadis K; Lytvyak E; Snijders RJALM; Takahashi A; Gatselis NK; Robles M; Andrade RJ; Schramm C; Lohse AW; Tanaka A; Drenth JPH; Montano-Loza AJ; Dalekos GN;
    JHEP Rep; 2023 Aug; 5(8):100778. PubMed ID: 37456672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease.
    Musio A; Perazza F; Leoni L; Stefanini B; Dajti E; Menozzi R; Petroni ML; Colecchia A; Ravaioli F
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarcopenia and fatty liver disease.
    Kim JA; Choi KM
    Hepatol Int; 2019 Nov; 13(6):674-687. PubMed ID: 31705444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of liver transplant candidates with non-alcoholic steatohepatitis.
    Esteban JPG; Asgharpour A
    Transl Gastroenterol Hepatol; 2022; 7():24. PubMed ID: 35892057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice.
    El Sherif O; Dhaliwal A; Newsome PN; Armstrong MJ
    Expert Rev Gastroenterol Hepatol; 2020 Mar; 14(3):197-205. PubMed ID: 32064966
    [No Abstract]   [Full Text] [Related]  

  • 18. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
    Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
    JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
    Le TA; Loomba R
    J Clin Exp Hepatol; 2012 Jun; 2(2):156-73. PubMed ID: 25755424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.
    Nachit M; Kwanten WJ; Thissen JP; Op De Beeck B; Van Gaal L; Vonghia L; Verrijken A; Driessen A; Horsmans Y; Francque S; Leclercq IA
    J Hepatol; 2021 Aug; 75(2):292-301. PubMed ID: 33865909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.